1. Cozzolino M, Tomlinson J, Walsh L, et al. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs. 2015;20(2):197–208.
2. Rodriguez M, Goodman WG, Liakopoulos V, et al. The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review. Semin Dial. 2015;28(5):497–507.
3. Amgen. European Commission approves Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism in adults on hemodialysis [media release]. 11 Nov 2016. http://www.amgen.com .
4. Committee for Medicinal Products for Human Use (CHMP). Parsabiv: etelcalcetide—summary of opinion (initial authorisation). 2016. http://www.ema.europa.eu . Accessed 19 Oct 2016.
5. Amgen. Amgen submits marketing authorization application for novel intravenous calcimimetic etelcalcetide (AMG 416) to the European Medicines Agency [media release]. 2 Sep 2015. http://www.amgen.com .